10x Genomics Analyst Price Targets

Wall Street analyst price targets and consensus rating for 10x Genomics (TXG).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

7Buy

10Hold

1Sell

Consensus RatingNeutral# Analysts18Avg. Consensus PT$46Upside to Avg. PT-47.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$40→$90
Sep 28, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$47→$80
Sep 28, 2026	Argus Research	John Eade	Initiate	Buy	$110
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Neutral	$20→$68
Sep 1, 2026	RBC Capital	Dan Leonard	Initiate	Sector Perform	$70
Aug 12, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$50→$65
Aug 10, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$42→$47
Aug 10, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$50→$60
Aug 7, 2026	Citigroup	Brendan Digan	PT Raise	Neutral	$45→$50
Aug 7, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$37→$40
Jul 17, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$23→$40
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$32→$50
Jul 9, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$22→$37
Jul 8, 2026	Citigroup	Patrick Donnelly	PT Raise	Neutral	$24→$45
Jul 1, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$20→$42
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$30→$40
May 12, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$20→$22
May 12, 2026	JP Morgan	Casey Woodring	PT Raise	Neutral	$17→$20
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$22→$32
Apr 20, 2026	B of A Securities	Derik De Bruin	PT Raise	Neutral	$21→$30

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.

Benzinga Newsdesk

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).

Avi Kapoor

PRO
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

Argus Research analyst John Eade initiates coverage on 10x Genomics (NASDAQ:TXG) with a Buy rating and announces Price Target of $110.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.

Benzinga Newsdesk

PRO
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70

RBC Capital analyst Dan Leonard initiates coverage on 10x Genomics (NASDAQ:TXG) with a Sector Perform rating and announces Price Target of $70.

Benzinga Newsdesk

10x Genomics Inc

10x Genomics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

PRO
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

PRO
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70

People Also Watch

People Also Watch

10x Genomics Inc

10x Genomics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PROPiper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROArgus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

PROUBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

PRORBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80

PRO
Argus Research Initiates Coverage On 10x Genomics with Buy Rating, Announces Price Target of $110

PRO
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

PRO
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70